Physical Therapists in New Hope, PA Accepting Medicare
8 Physical Therapists found. Showing 1 - 8
 Mrs. Natalie Ann Nettles, PT, MS Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Logan Square, Suite #1, New Hope, PA 18938 Phone: 215-862-4195 Fax: 215-862-4197 |
Alexandra S Nachtman, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 210 Union Square Dr, New Hope, PA 18938 Phone: 215-862-1648 Fax: 215-862-1625 |
Bridget Sanphy, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 210 Union Square Dr, New Hope, PA 18938 Phone: 215-862-1648 Fax: 215-862-1625 |
 Peak Physical Therapy & Performance Physical Therapist Medicare: Medicare Enrolled Practice Location: 210 Union Square Dr, New Hope, PA 18938 Phone: 215-862-1648 Fax: 215-862-1625 |
 Mr. William C Mccafferty, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 15 Village Sq, Logan Sq, Suite 1, New Hope, PA 18938 Phone: 215-862-4195 Fax: 215-862-4197 |
Jane S. Tracy, P. T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 111 Riverwoods Dr, New Hope, PA 18938 Phone: 215-862-1135 Fax: 215-862-1135 |
Wendy Alice Perlmutter, PT Physical Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3508 N Sugan Rd, New Hope, PA 18938 Phone: 215-297-0624 |
Mrs. Jean A Miranda, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 30 N Sugan Rd, Suite 1c, New Hope, PA 18938 Phone: 267-614-4241 |
News Archive
Aditazz, Develop partner to market Patient Mobility Platform
Aditazz announced a strategic partnership with inventor Roger Leib to jointly develop and market the Patient Mobility Platform, a suite of mobility products conceived and designed by Leib, founder of Develop, LLC.
Trial looks at new treatment for solid cancer tumors and non-Hodgkin's lymphoma
Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial, which aims to evaluate a new treatment for solid cancer tumors and non-Hodgkin's lymphoma (NHL) in combination with a chemotherapy agent called cyclophosphamide.
Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.
Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency
Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The proposed indication would make TMC278 available for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults.
› Verified 3 days ago
Chiropractors
Physical Therapists
Speech-Language Pathologists
Optometrists
Occupational Therapists